Satellite Sessions

October 4 | 12:30-14:30

Abbot Laboratories | October 4 | 12:30-14:30

Mitral and Tricuspid regurgitation in heart failure patients- from the community to the catherization lab and back

 

Click here to view session agenda

Pfizer Pharmaceuticals Israel | October 4 | 12:30-14:30

The revolution in Cardiac Amyloidosis is here! From suspicions to early diagnosis

 

Click here to view session agenda

Boehringer Ingelheim Israel LTD | October 4 | 12:30-14:30

SGLT2 inhibition in heart failure: optimizing patient benefit in clinical practice

 

Click here to view session agenda

Novartis Israel | October 4 | 12:30-14:30

Bending the curve of life- New era in Hypercholesterolemia management


Click here to view session agenda

October 5 | 12:30-14:30

Bayer Israel | October 5 | 12:30-14:30

2021 Guidelines for HFrEF Treatment
What is New for Patients with a Worsening Heart Failure?

 

Click here to view session agenda

Novo Nordisk | October 5 | 12:30-14:30

The innovation story of Semaglutide for the treatment & CV risk modification in T2D

Click here to view session agenda

AstraZeneca (Israel) | October 5 | 12:30-14:30

SGLT2 Inhibition in Heart Failure: Recalculating the HFrEF Treatment Paradigm

 

Click here to view session agenda

Medison | October 5 | 12:30-14:30

Step forward to personalized anticoagulant treatment: new kid on the block

 

Click here to view session agenda

Medtronic | October 5 | 12:30-14:30

Robotic MVR & Innovations in Cardiac Surgery

 

Click here to view session agenda